Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities?

被引:34
|
作者
Lee, Y. -T. [1 ,2 ]
Kuo, S. -C. [1 ,3 ]
Yang, S. -P. [2 ,4 ]
Lin, Y. -T. [1 ,2 ,4 ]
Chiang, D. -H. [2 ,5 ]
Tseng, F. -C. [3 ]
Chen, T-L. [1 ,2 ,4 ]
Fung, C. -P. [1 ,2 ,4 ]
机构
[1] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
[3] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Miaoli, Miaoli County, Taiwan
[4] Taipei Vet Gen Hosp, Div Infect Dis, Taipei 11217, Taiwan
[5] Taipei Vet Gen Hosp, Dept Crit Care Med, Taipei 11217, Taiwan
关键词
Acinetobacter baumannii; Acinetobacter nosocomialis; antimicrobial therapy; mortality; pneumonia; EPIDEMIOLOGY; MORTALITY; IMPACT; IDENTIFICATION; INFECTIONS; SEVERITY; COMPLEX; SPACER;
D O I
10.1111/j.1469-0691.2012.03988.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The phenotypically indistinguishable Acinetobacter baumannii and Acinetobacter nosocomialis have become leading pathogens causing nosocomial pneumonia in critically ill patients. A.baumannii and A.nosocomialis nosocomial pneumonias were grouped as a single clinical entity previously. This study aimed to determine whether they are the same or a different clinical entity. A total of 121 patients with A.baumannii and 131 with A.nosocomialis bacteremic nosocomial pneumonia were included during an 8-year period. Despite the similar Charlson co-morbidity scores at admission, patients with A.baumannii pneumonia were more likely to have abnormal haematological findings, lobar pneumonia, significantly higher Acute Physiology and Chronic Health Evaluation II scores and higher frequency of shock at the onset of bacteraemia than those with A.nosocomialis pneumoni. A.baumannii isolates were resistant to more classes of antimicrobials, except colistin, and therefore the patients with A.baumannii pneumonia were more likely to receive inappropriate antimicrobial therapy. The 14-day mortality was significantly higher in patients with A.baumannii pneumonia (34.7% vs. 15.3%, p 0.001). A.baumannii was an independent risk factor for mortality (OR, 2.03; 95% CI, 1.05-3.90; p 0.035) in the overall cohort after adjustment for other risk factors for death, including inappropriate antimicrobial therapy. The results demonstrated the difference in clinical presentation, microbial characteristics and outcomes between A.baumannii and A.nosocomialis nosocomial pneumonia, and supported that they are two distinct clinical entities.
引用
收藏
页码:640 / 645
页数:6
相关论文
共 50 条
  • [41] Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii
    Corbella, X
    Ariza, J
    Ardanuy, C
    Vuelta, M
    Tubau, F
    Sora, M
    Pujol, M
    Gudiol, F
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) : 793 - 802
  • [42] NOSOCOMIAL BLOODSTREAM INFECTION CAUSED BY MDR-ACINETOBACTER BAUMANNII: CLINICAL FEATURES, MORTALITY, AND ANTIMICROBIAL SUSCEPTIBILITY.
    Ramadan, Bassel
    Lababidi, Hani
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A168 - A168
  • [43] Nosocomial meningitis caused by Acinetobacter baumannii: risk factors and their impact on patient outcomes and treatments
    Yang, Minjie
    Hu, Zupeng
    Hu, Fupin
    FUTURE MICROBIOLOGY, 2012, 7 (06) : 787 - 793
  • [44] Efficacy and Safety of Intravenous Colistin in Preterm Infants with Nosocomial Sepsis Caused by Acinetobacter baumannii
    Alan, Serdar
    Yildiz, Duran
    Erdeve, Omer
    Cakir, Ufuk
    Kahvecioglu, Dilek
    Okulu, Emel
    Ates, Can
    Atasay, Begum
    Arsan, Saadet
    AMERICAN JOURNAL OF PERINATOLOGY, 2014, 31 (12) : 1079 - 1085
  • [45] Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia
    Meng, Lan
    Kang, Dongmei
    Shen, Guodong
    Yao, Haifeng
    Cui, Guofeng
    Chen, Mengting
    Fan, Xiaoyun
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [46] Perillaldehyde: A promising antibacterial agent for the treatment of pneumonia caused by Acinetobacter baumannii infection
    Chu, Zi-Yong
    Li, Yu-Long
    Wang, Lin
    Wei, Shu-Yun
    Yang, Sheng-Qiang
    Zeng, Hong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 126
  • [47] Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
    Zhou, Yangang
    Chen, Xumin
    Xu, Ping
    Zhu, Yan
    Wang, Kuangguo
    Xiang, Daxiong
    Wang, Feng
    Hoan Linh Banh
    BMC PHARMACOLOGY & TOXICOLOGY, 2019, 20 (1):
  • [48] Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii
    Franzone, John P.
    Mackow, Natalie A.
    van Duin, David
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (02) : 137 - 143
  • [49] Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
    Yangang Zhou
    Xumin Chen
    Ping Xu
    Yan Zhu
    Kuangguo Wang
    Daxiong Xiang
    Feng Wang
    Hoan Linh Banh
    BMC Pharmacology and Toxicology, 20
  • [50] Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings
    José Garnacho-Montero
    C. Ortiz-Leyba
    Esteban Fernández-Hinojosa
    Teresa Aldabó-Pallás
    Aurelio Cayuela
    Juan A. Marquez-Vácaro
    Andrés Garcia-Curiel
    F. J. Jiménez-Jiménez
    Intensive Care Medicine, 2005, 31 : 649 - 655